Global Oral Parkinson's Disease Medications Market Growth 2024-2030

Global Oral Parkinson's Disease Medications Market Growth 2024-2030

Oral Parkinson's disease medications are drugs taken by mouth to manage the symptoms of Parkinson's disease, a neurodegenerative disorder characterized by motor symptoms such as tremors, stiffness, and bradykinesia (slowed movements). The primary oral medication is levodopa, often combined with carbidopa, which helps increase dopamine levels in the brain and improve motor function. Other oral medications include dopamine agonists (e.g., pramipexole, ropinirole) that mimic dopamine effects, MAO-B inhibitors (e.g., selegiline, rasagiline) that prevent dopamine breakdown, and COMT inhibitors (e.g., entacapone) that prolong the effect of levodopa. Anticholinergics (e.g., benztropine) and amantadine are also used to manage specific symptoms. These medications aim to reduce symptoms, improve quality of life, and enhance daily functioning, although they do not cure the disease or stop its progression.

The global Oral Parkinson's Disease Medications market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the “Oral Parkinson's Disease Medications Industry Forecast” looks at past sales and reviews total world Oral Parkinson's Disease Medications sales in 2023, providing a comprehensive analysis by region and market sector of projected Oral Parkinson's Disease Medications sales for 2024 through 2030. With Oral Parkinson's Disease Medications sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oral Parkinson's Disease Medications industry.

This Insight Report provides a comprehensive analysis of the global Oral Parkinson's Disease Medications landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Oral Parkinson's Disease Medications portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Oral Parkinson's Disease Medications market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oral Parkinson's Disease Medications and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oral Parkinson's Disease Medications.

United States market for Oral Parkinson's Disease Medications is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Oral Parkinson's Disease Medications is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Oral Parkinson's Disease Medications is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Oral Parkinson's Disease Medications players cover AbbVie, Merck, Boehringer Ingelheim, GlaxoSmithKline, Novartis Pharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly

% in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Oral Parkinson's Disease Medications market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
L-Dopa Formulations
Dopamine Agonists
Mao-B Inhibitors
COMT Inhibitors

Segmentation by Application:
Under 40 Years Old
40-65 Years Old
Above 65 Years Old

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
AbbVie
Merck
Boehringer Ingelheim
GlaxoSmithKline
Novartis Pharma
Supernus Pharmaceuticals
Bausch Health
Newron Pharmaceuticals
Teva Pharmaceutica
Glenmark Pharmaceuticals
Orion Pharma
Neurocrine Biosciences
Kyowa Kirin
UCB
Desitin Arzneimittel
Amneal Pharmaceuticals
Organon Pharma
F.Hoffmann-La Roche
Lundbeck
Stada

Key Questions Addressed in this Report

What is the 10-year outlook for the global Oral Parkinson's Disease Medications market?

What factors are driving Oral Parkinson's Disease Medications market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Oral Parkinson's Disease Medications market opportunities vary by end market size?

How does Oral Parkinson's Disease Medications break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.